LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus.

LJP 394 (abetimus, Riquent, La Jolla Pharmaceuticals) is four oligonucleotide B cell toleragen which acts as an 'anti-anti DNA'. Given as a weekly infusion, Phase 1, 2, and 3 studies with this biologic on close to 1,000 patients have demonstrated no toxicity of any note. In patients with lupus nephritis and an elevated anti-DNA (Farr assay) who have a high affinity to LJP 394, the drug significantly decreases anti-DNA, improves quality of life, and trends towards reducing renal flares. LJP 394 is a promising induction and/or maintenance therapy for lupus patients with elevated anti-DNA and active disease.